Treatment of dysimmune neuropathies

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. Recent reports on the association of intravenous methylprednisolone or interferon-β (IFN-β) to IVIg did not result in significant further improvement. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) steroids, PE, and IVIG are initially similarly effective. The short-term effect of PE and IVIg and the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. The recent identification of multifocal motor neuropathy (MMN) was shortly followed by the finding of an effective therapy. Almost 80% of patients respond to IVIg whose effect needs to be maintained with periodic infusions for long periods of time, and tends to decrease after several years. Also in this condition a number of immune modulating agents have been used to reduce the frequency or improve the effectiveness of IVIg, but their efficacy has not been so far confirmed in randomized trials. Similar conclusions can be drawn for neuropathies associated with monoclonal gammopathies where only PE and IVIg have proved to be effective in controlled studies, while the promising initial results obtained with Rituximab in neuropathy associated IgM monoclonal gammopathy awaits confirmation from controlled trials.

Original languageEnglish
Pages (from-to)385-395
Number of pages11
JournalJournal of Neurology
Volume252
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Paraproteinemias
Interferons
Steroids
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Methylprednisolone
Immunoglobulin M
Monoclonal Antibodies
Mortality
Therapeutics
Rituximab

Keywords

  • Chronic inflammatory demyelinating polyradiculoneuropathy
  • Guillain-Barré syndrome
  • Monoclonal gammopathy
  • Multifocal motor neuropathy
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Treatment of dysimmune neuropathies. / Nobile-Orazio, Eduardo.

In: Journal of Neurology, Vol. 252, No. 4, 04.2005, p. 385-395.

Research output: Contribution to journalArticle

@article{55a2c6bb1ee84f5ab2894a6ca92ba5fa,
title = "Treatment of dysimmune neuropathies",
abstract = "IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. Recent reports on the association of intravenous methylprednisolone or interferon-β (IFN-β) to IVIg did not result in significant further improvement. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) steroids, PE, and IVIG are initially similarly effective. The short-term effect of PE and IVIg and the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. The recent identification of multifocal motor neuropathy (MMN) was shortly followed by the finding of an effective therapy. Almost 80{\%} of patients respond to IVIg whose effect needs to be maintained with periodic infusions for long periods of time, and tends to decrease after several years. Also in this condition a number of immune modulating agents have been used to reduce the frequency or improve the effectiveness of IVIg, but their efficacy has not been so far confirmed in randomized trials. Similar conclusions can be drawn for neuropathies associated with monoclonal gammopathies where only PE and IVIg have proved to be effective in controlled studies, while the promising initial results obtained with Rituximab in neuropathy associated IgM monoclonal gammopathy awaits confirmation from controlled trials.",
keywords = "Chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barr{\'e} syndrome, Monoclonal gammopathy, Multifocal motor neuropathy, Therapy",
author = "Eduardo Nobile-Orazio",
year = "2005",
month = "4",
doi = "10.1007/s00415-005-0805-0",
language = "English",
volume = "252",
pages = "385--395",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - Treatment of dysimmune neuropathies

AU - Nobile-Orazio, Eduardo

PY - 2005/4

Y1 - 2005/4

N2 - IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. Recent reports on the association of intravenous methylprednisolone or interferon-β (IFN-β) to IVIg did not result in significant further improvement. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) steroids, PE, and IVIG are initially similarly effective. The short-term effect of PE and IVIg and the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. The recent identification of multifocal motor neuropathy (MMN) was shortly followed by the finding of an effective therapy. Almost 80% of patients respond to IVIg whose effect needs to be maintained with periodic infusions for long periods of time, and tends to decrease after several years. Also in this condition a number of immune modulating agents have been used to reduce the frequency or improve the effectiveness of IVIg, but their efficacy has not been so far confirmed in randomized trials. Similar conclusions can be drawn for neuropathies associated with monoclonal gammopathies where only PE and IVIg have proved to be effective in controlled studies, while the promising initial results obtained with Rituximab in neuropathy associated IgM monoclonal gammopathy awaits confirmation from controlled trials.

AB - IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. Recent reports on the association of intravenous methylprednisolone or interferon-β (IFN-β) to IVIg did not result in significant further improvement. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) steroids, PE, and IVIG are initially similarly effective. The short-term effect of PE and IVIg and the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. The recent identification of multifocal motor neuropathy (MMN) was shortly followed by the finding of an effective therapy. Almost 80% of patients respond to IVIg whose effect needs to be maintained with periodic infusions for long periods of time, and tends to decrease after several years. Also in this condition a number of immune modulating agents have been used to reduce the frequency or improve the effectiveness of IVIg, but their efficacy has not been so far confirmed in randomized trials. Similar conclusions can be drawn for neuropathies associated with monoclonal gammopathies where only PE and IVIg have proved to be effective in controlled studies, while the promising initial results obtained with Rituximab in neuropathy associated IgM monoclonal gammopathy awaits confirmation from controlled trials.

KW - Chronic inflammatory demyelinating polyradiculoneuropathy

KW - Guillain-Barré syndrome

KW - Monoclonal gammopathy

KW - Multifocal motor neuropathy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=17744396371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744396371&partnerID=8YFLogxK

U2 - 10.1007/s00415-005-0805-0

DO - 10.1007/s00415-005-0805-0

M3 - Article

VL - 252

SP - 385

EP - 395

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -